Literature DB >> 474154

Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose.

L Kangas, H Allonen, R Lammintausta, M Salonen, A Pekkarinen.   

Abstract

The pharmacokinetics of nitrazepam in saliva and serum was studied in 12 healthy volunteers after a single administration of a 5 mg nitrazepam tablet. The binding of nitrazepam to plasma proteins was determined 4 hours after the administration by ultracentrifugation. The analysis of nitrazepam concentrations was performed by 63Ni-EC-GLC. The pharmacokinetic parameters were evaluated manually or by AUTOAN-program in serum, and manually in saliva. The concentrations of nitrazepam in serum and saliva correlated significantly (r = 0.472, P less than 0.001, n = 97). The ratio saliva: serum was, however, time dependent. The protein free fraction in serum was significantly higher (P less than 0.01) than the salivary concentration at the same time (4 hours after administration). The peak concentrations in serum and saliva were 40.7 and 1.9 ng/ml (P less than 0.001) and the times to reach the peak maximum 2.4 and 2.5 hours, respectively (difference not significant). The mean half-life of nitrazepam in serum was 30.5 hrs and in saliva 39.9 hrs, the difference being significant at P less than 0.05. The distribution phase parameters, poorly described before, were calculated. The clinical value of nitrazepam analysis in saliva seems to be negligible.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 474154     DOI: 10.1111/j.1600-0773.1979.tb02354.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  9 in total

Review 1.  Relationships between CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.

Authors:  W A Colburn; M L Jack
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 3.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

4.  Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.

Authors:  R Jochemsen; B R Van Beusekom; P Spoelstra; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

5.  Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam.

Authors:  R Jochemsen; M van der Graaff; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of nitrazepam.

Authors:  L Kangas; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

7.  Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.

Authors:  R Jochemsen; J J Hogendoorn; J Dingemanse; J Hermans; J K Boeijinga; D D Breimer
Journal:  J Pharmacokinet Biopharm       Date:  1982-06

Review 8.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

9.  Bromocriptine concentration in saliva plasma after long-term treatment of patients with Parkinson's disease.

Authors:  M L Friis; T Johnsen; N E Larsen; E F Hvidberg; H Pakkenberg
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.